Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Лечебные аспекты применения оральных контрацептивов, содержащих дроспиренон, у женщин с нарушением репродуктивной функции
Лечебные аспекты применения оральных контрацептивов, содержащих дроспиренон, у женщин с нарушением репродуктивной функции
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Свойства дроспиренона максимально приближены к естественному прогестерону и сочетаются с широким спектром клинических эффектов и хорошей переносимостью. Дроспиренон – предпочтительный прогестагенный компонент как в составе КОК у девушек с симптомами ПМС и гиперандрогенными состояниями, так и в составе комплексной терапии у женщин с сердечно-сосудистой патологией, артериальной гипертензией и метаболическим синдромом.
Ключевые слова: дроспиренон, предменструальный синдром, гиперандрогения, комбинированные оральные контрацептивы, артериальная гипертензия.
Key words: drospirenone, premenstrual syndrome, hyperandrogenism, combined oral contraceptives, arterial hypertension.
Ключевые слова: дроспиренон, предменструальный синдром, гиперандрогения, комбинированные оральные контрацептивы, артериальная гипертензия.
________________________________________________
Key words: drospirenone, premenstrual syndrome, hyperandrogenism, combined oral contraceptives, arterial hypertension.
Полный текст
Список литературы
1. Геворкян М.А, Манухин И.Б., Кузнецова Е.М. Опыт применения дроспиренон-содержащего гормонального контрацептива. Рус. мед. журн. 2011; 19 (2): 1–2.
2. Кузнецова И.В., Побединский Н.М. Новый оральный контрацептив: один из многих или препарат с уникальными свойствами? Трудный пациент. 2004; 2: 11–4.
3. Подзолкова Н.М., Глазкова О.Л., Сумятина Л.В. Метаболические эффекты низкодозированных дроспиренонсодержащих гормональных контрацептивов. Рус. мед. журн. 2012; 17.
4. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата ЗГТ с дроспиреноном у пациенток с метаболическим синдромом в постменопаузе. Кардиоваскулярная терапия и профилактика. 2009; 8 (1): 75–80.
5. Lucky AW, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinylestradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82 (2): 143–50.
6. Meendering JR, Torgrimson BN, Miller NP et al. A combined oral contraceptive containing 30 mcg ethinylestradiol and 3.0 mg drospirenone does not impair endothelium-dependent vasodilation. Contraception 2010; 82 (4): 366–72.
7. Giribela CR, Melo NR, Silva RC et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 2012; 86 (1): 35–41.
8. Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5 (2): 124–34.
9. Gruber DM, Huber JC, Melis GB et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 m μg and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 m μg and desogestrel 150 m μg. Treat Endocrinol 2006; 5: 115–21.
10. Mabrouk M, Solfrini S, Frascà C et al. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg. Gynecol Endocrinol 2012; 28 (6): 451–4.
11. Maloney JM, Dietze P, Watson D et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009; 8 (9): 837–44.
12. Gaspard U, Endrikat L, Desager JP et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69 (4): 271–8.
13. Preston RA, Alonso A, Darlene P et al. Additive effect of Drospirenone/ 17b-Estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2005; 18: 797–804.
14. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011; 76 (7): 636–52.
15. Caprio M, Antelmi A, Chetrite G et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152 (1): 113–25.
16. Bachmann G, Korner P. Bleeding patterns associated with oral contraceptive use: a review of the literature. Contraception 2007; 76 (3): 182–9.
17. Endrikat JS, Milchev NP, Kapamadzija A et al. Bleeding pattern, tolerance and patient satisfaction with a drospirenonecontaining oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception 2009; 79 (6): 428–32.
18. Bruni Bresciani V. Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen. Minerva Ginecol 2010; 62 (3): 261–6.
19. Carranza-Lira S. Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausalvasomotor symptoms: a review. Clin Interv Aging 2009; 4: 59–62.
20. Chaiyasit N, Taneepanichskul S. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone – N24/4 regimen. J Med Assoc Thai 2010; 93 (5): 517–22.
21. Halpeich U, Backstrom T et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for research studies. Genecolodical Endocrinjlogy 2007; 23 (3): 123–30.
22. Gambacciani M, Rosano G, Cappagli B et al. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011; 14 (1): 18–24.
23. Ozdemir S, Görkemli H, Gezginç K et al. Clinical and metabolic effects of medroxyprogesterone acetate and ethinylestradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008; 103 (1): 44–9.
24. Chaikittisilpa S, Angsuwathana S, Chaovisitsaree S et al. Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women. J Med Assoc Thai 2011; 94 (9): 1019–25.
25. V. de Leo, Scolaro V, Musacchio MC et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 2011; 96 (4): 917–20.
26. Fruzzetti F, Perini D, Lazzarini V et al. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril 2010; 94 (5): 1793–8.
27. Anttila L, Bachmann G, Hernádi L et al. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 180–2.
28. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in postmenopausal women with hypertension. Hypertension 2006; 48: 1–8.
29. Ahmed AH, Gordon RD, Taylor PJ et al. Effect of contraceptives on aldosterone/renin ratio may vary according tothe components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 2011; 96 (6): 1797–804.
30. Dinger J, Minh TD, Buttmann N et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117 (1): 33–40.
31. Lima SM, Reis BF, Yamada SS et al. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium. Climacteric 2011; 14 (5): 551–7.
32. Kelly S, Davies E, Fearns S et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallelgroup, multicentre study. Clin Drug Investig 2010; 30 (5): 325–36.
33. Yildizhan R, Yildizhan B, Adali E et al. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet 2009; 280 (2): 255–61.
34. Lello S, Primavera G, Colonna L et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008; 24 (12): 718–23.
35. Gargano V, Massaro M, Morra I et al. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2008; 78 (1): 10–5.
36. Cibula D, Karck U, Weidenhammer HG et al. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20 mg and drospirenone 3 mg. Clin Drugs Investig 2006; 26 (3): 143–50.
37. Hernádi L, Marr J, Trummer D et al. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception 2009; 80 (1): 18–24.
38. Fan GS, Bian ML, Cheng LN et al. Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial. Zhonghua Fu Chan Ke Za Zhi 2009; 44 (1): 38–44.
39. Guang-Sheng F, Mei-Lu B, Li-Nan C et al. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin Drug Investig 2010; 30 (6): 387–96.
40. Huber J, Foidart JM, Wuttke W et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5 (1): 25–34.
41. Villaseca P, Hormaza P, Cardenas I et al. Eyhinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes. Eur J Contraception Reprod Health Care 2004; 9: 155–65.
42. Marr J, Heinemann K, Kunz M, Rapkin A. Ethinylestradiol 20 μg/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet 2011; 113 (2): 103–7.
43. Kiran H, Tok A, Yüksel M et al. Estradiol plus drospirenone therapy increases mammographic breast density in perimenopausal women. Eur J Obstet Gynecol Reprod Biol 2011; 159 (2): 384–7.
44. Foidart JM. Added benefits of drospirenone for compliance. Gynecol Endocrinol 2004; 18 (1): 33.
45. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004; 27 (13): 1001–18.
46. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71 (6): 409–16.
47. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005 (12): 716–27.
48. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 15 (2): CD006586.
49. Villa P, Suriano R, Ricciardi L et al. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemicmetabolism and other cardiovascular risk factors in healthy postmenopausal women. Fertil Steril 2011; 95 (1): 158–63.
50. Marr J, Gerlinger C, Kunz M. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen. Eur J Obstet Gynecol Reprod Biol 2012; 162 (1): 91–5.
51. Potter L, Oakley D, E. de Leon-Wong, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996 (28): 154–8.
52. Meier CR. Health risks of oral contraceptive. Ther Umsch 2011; 68 (6): 345–52.
53. Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med 2008; 53 (Suppl. 9): 721–8.
54. Oner G. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. Contraception 2011; 84 (5): 508–11.
55. Etminan M, Delaney JA, Bressler B et al. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011; 183 (8): 899–904.
56. Battaglia C, Mancini F, Fabbri R et al. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril 2010; 94 (4): 1417–25.
57. Marr J, Niknian M, Shulman LP, Lynen R. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen. Contraception 2011; 84 (1): 81–6.
58. Preston RA, Norris PM, Alonso AB et al. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007; 14 (3). Pt. 1: 408–14.
59. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl. 9): 729–41.
60. Rapkin AJ, Sorger SN, Winer SA. Drospirenone ethinylestradiol. Drugs Today (Barc) 2008; 44 (2): 133–45.
61. Rosenberg MJ. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30: 89–92, 104.
62. Rosendaal F. Female hormones and thrombosis. J Arterioscler Thromb Vascul Biol 2002; 22: 201–10.
63. Seeger H. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. Climacteric 2009; 12 (1): 80–7.
64. Sitruk-Ware R. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord 2011; 12 (2): 63–75.
65. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78 (1): 16–25.
66. Taneepanichskul S. Influence of a new oral contraceptive with drospirenone on lipid metabolism. Gynecol Endocrinol 2007; 23 (6): 347–50.
67. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 171–5.
68. Bitzer J, Frey B, M. von Schönau et al. Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: does it make a difference in the mind and the daily practise of gynaecologists and general practitioners? Eur J Contracept Reprod Health Care 2009; 14 (4): 258–67.
69. Joish VN, Boklage S, Lynen R et al. Use of drospirenone/ethinylestradiol (DRSP/EE) among women with acne reduces acne treatment-related resources. J Med Econ 2011; 14 (6): 681–9.
70. Verchaeghe J. Hormonal contraception in women with metabolic syndrome. Contraception Reprod Health Care 2010; 5 (5): 305–14.
2. Кузнецова И.В., Побединский Н.М. Новый оральный контрацептив: один из многих или препарат с уникальными свойствами? Трудный пациент. 2004; 2: 11–4.
3. Подзолкова Н.М., Глазкова О.Л., Сумятина Л.В. Метаболические эффекты низкодозированных дроспиренонсодержащих гормональных контрацептивов. Рус. мед. журн. 2012; 17.
4. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата ЗГТ с дроспиреноном у пациенток с метаболическим синдромом в постменопаузе. Кардиоваскулярная терапия и профилактика. 2009; 8 (1): 75–80.
5. Lucky AW, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinylestradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82 (2): 143–50.
6. Meendering JR, Torgrimson BN, Miller NP et al. A combined oral contraceptive containing 30 mcg ethinylestradiol and 3.0 mg drospirenone does not impair endothelium-dependent vasodilation. Contraception 2010; 82 (4): 366–72.
7. Giribela CR, Melo NR, Silva RC et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 2012; 86 (1): 35–41.
8. Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5 (2): 124–34.
9. Gruber DM, Huber JC, Melis GB et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 m μg and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 m μg and desogestrel 150 m μg. Treat Endocrinol 2006; 5: 115–21.
10. Mabrouk M, Solfrini S, Frascà C et al. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg. Gynecol Endocrinol 2012; 28 (6): 451–4.
11. Maloney JM, Dietze P, Watson D et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009; 8 (9): 837–44.
12. Gaspard U, Endrikat L, Desager JP et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69 (4): 271–8.
13. Preston RA, Alonso A, Darlene P et al. Additive effect of Drospirenone/ 17b-Estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2005; 18: 797–804.
14. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011; 76 (7): 636–52.
15. Caprio M, Antelmi A, Chetrite G et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152 (1): 113–25.
16. Bachmann G, Korner P. Bleeding patterns associated with oral contraceptive use: a review of the literature. Contraception 2007; 76 (3): 182–9.
17. Endrikat JS, Milchev NP, Kapamadzija A et al. Bleeding pattern, tolerance and patient satisfaction with a drospirenonecontaining oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception 2009; 79 (6): 428–32.
18. Bruni Bresciani V. Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen. Minerva Ginecol 2010; 62 (3): 261–6.
19. Carranza-Lira S. Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausalvasomotor symptoms: a review. Clin Interv Aging 2009; 4: 59–62.
20. Chaiyasit N, Taneepanichskul S. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone – N24/4 regimen. J Med Assoc Thai 2010; 93 (5): 517–22.
21. Halpeich U, Backstrom T et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for research studies. Genecolodical Endocrinjlogy 2007; 23 (3): 123–30.
22. Gambacciani M, Rosano G, Cappagli B et al. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011; 14 (1): 18–24.
23. Ozdemir S, Görkemli H, Gezginç K et al. Clinical and metabolic effects of medroxyprogesterone acetate and ethinylestradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008; 103 (1): 44–9.
24. Chaikittisilpa S, Angsuwathana S, Chaovisitsaree S et al. Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women. J Med Assoc Thai 2011; 94 (9): 1019–25.
25. V. de Leo, Scolaro V, Musacchio MC et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 2011; 96 (4): 917–20.
26. Fruzzetti F, Perini D, Lazzarini V et al. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril 2010; 94 (5): 1793–8.
27. Anttila L, Bachmann G, Hernádi L et al. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 180–2.
28. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in postmenopausal women with hypertension. Hypertension 2006; 48: 1–8.
29. Ahmed AH, Gordon RD, Taylor PJ et al. Effect of contraceptives on aldosterone/renin ratio may vary according tothe components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 2011; 96 (6): 1797–804.
30. Dinger J, Minh TD, Buttmann N et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117 (1): 33–40.
31. Lima SM, Reis BF, Yamada SS et al. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium. Climacteric 2011; 14 (5): 551–7.
32. Kelly S, Davies E, Fearns S et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallelgroup, multicentre study. Clin Drug Investig 2010; 30 (5): 325–36.
33. Yildizhan R, Yildizhan B, Adali E et al. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet 2009; 280 (2): 255–61.
34. Lello S, Primavera G, Colonna L et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008; 24 (12): 718–23.
35. Gargano V, Massaro M, Morra I et al. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2008; 78 (1): 10–5.
36. Cibula D, Karck U, Weidenhammer HG et al. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20 mg and drospirenone 3 mg. Clin Drugs Investig 2006; 26 (3): 143–50.
37. Hernádi L, Marr J, Trummer D et al. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception 2009; 80 (1): 18–24.
38. Fan GS, Bian ML, Cheng LN et al. Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial. Zhonghua Fu Chan Ke Za Zhi 2009; 44 (1): 38–44.
39. Guang-Sheng F, Mei-Lu B, Li-Nan C et al. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin Drug Investig 2010; 30 (6): 387–96.
40. Huber J, Foidart JM, Wuttke W et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5 (1): 25–34.
41. Villaseca P, Hormaza P, Cardenas I et al. Eyhinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes. Eur J Contraception Reprod Health Care 2004; 9: 155–65.
42. Marr J, Heinemann K, Kunz M, Rapkin A. Ethinylestradiol 20 μg/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet 2011; 113 (2): 103–7.
43. Kiran H, Tok A, Yüksel M et al. Estradiol plus drospirenone therapy increases mammographic breast density in perimenopausal women. Eur J Obstet Gynecol Reprod Biol 2011; 159 (2): 384–7.
44. Foidart JM. Added benefits of drospirenone for compliance. Gynecol Endocrinol 2004; 18 (1): 33.
45. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004; 27 (13): 1001–18.
46. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71 (6): 409–16.
47. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005 (12): 716–27.
48. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 15 (2): CD006586.
49. Villa P, Suriano R, Ricciardi L et al. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemicmetabolism and other cardiovascular risk factors in healthy postmenopausal women. Fertil Steril 2011; 95 (1): 158–63.
50. Marr J, Gerlinger C, Kunz M. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen. Eur J Obstet Gynecol Reprod Biol 2012; 162 (1): 91–5.
51. Potter L, Oakley D, E. de Leon-Wong, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996 (28): 154–8.
52. Meier CR. Health risks of oral contraceptive. Ther Umsch 2011; 68 (6): 345–52.
53. Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med 2008; 53 (Suppl. 9): 721–8.
54. Oner G. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. Contraception 2011; 84 (5): 508–11.
55. Etminan M, Delaney JA, Bressler B et al. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011; 183 (8): 899–904.
56. Battaglia C, Mancini F, Fabbri R et al. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril 2010; 94 (4): 1417–25.
57. Marr J, Niknian M, Shulman LP, Lynen R. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen. Contraception 2011; 84 (1): 81–6.
58. Preston RA, Norris PM, Alonso AB et al. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007; 14 (3). Pt. 1: 408–14.
59. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl. 9): 729–41.
60. Rapkin AJ, Sorger SN, Winer SA. Drospirenone ethinylestradiol. Drugs Today (Barc) 2008; 44 (2): 133–45.
61. Rosenberg MJ. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30: 89–92, 104.
62. Rosendaal F. Female hormones and thrombosis. J Arterioscler Thromb Vascul Biol 2002; 22: 201–10.
63. Seeger H. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. Climacteric 2009; 12 (1): 80–7.
64. Sitruk-Ware R. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord 2011; 12 (2): 63–75.
65. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78 (1): 16–25.
66. Taneepanichskul S. Influence of a new oral contraceptive with drospirenone on lipid metabolism. Gynecol Endocrinol 2007; 23 (6): 347–50.
67. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 171–5.
68. Bitzer J, Frey B, M. von Schönau et al. Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: does it make a difference in the mind and the daily practise of gynaecologists and general practitioners? Eur J Contracept Reprod Health Care 2009; 14 (4): 258–67.
69. Joish VN, Boklage S, Lynen R et al. Use of drospirenone/ethinylestradiol (DRSP/EE) among women with acne reduces acne treatment-related resources. J Med Econ 2011; 14 (6): 681–9.
70. Verchaeghe J. Hormonal contraception in women with metabolic syndrome. Contraception Reprod Health Care 2010; 5 (5): 305–14.
2. Кузнецова И.В., Побединский Н.М. Новый оральный контрацептив: один из многих или препарат с уникальными свойствами? Трудный пациент. 2004; 2: 11–4.
3. Подзолкова Н.М., Глазкова О.Л., Сумятина Л.В. Метаболические эффекты низкодозированных дроспиренонсодержащих гормональных контрацептивов. Рус. мед. журн. 2012; 17.
4. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата ЗГТ с дроспиреноном у пациенток с метаболическим синдромом в постменопаузе. Кардиоваскулярная терапия и профилактика. 2009; 8 (1): 75–80.
5. Lucky AW, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinylestradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82 (2): 143–50.
6. Meendering JR, Torgrimson BN, Miller NP et al. A combined oral contraceptive containing 30 mcg ethinylestradiol and 3.0 mg drospirenone does not impair endothelium-dependent vasodilation. Contraception 2010; 82 (4): 366–72.
7. Giribela CR, Melo NR, Silva RC et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 2012; 86 (1): 35–41.
8. Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5 (2): 124–34.
9. Gruber DM, Huber JC, Melis GB et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 m μg and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 m μg and desogestrel 150 m μg. Treat Endocrinol 2006; 5: 115–21.
10. Mabrouk M, Solfrini S, Frascà C et al. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg. Gynecol Endocrinol 2012; 28 (6): 451–4.
11. Maloney JM, Dietze P, Watson D et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009; 8 (9): 837–44.
12. Gaspard U, Endrikat L, Desager JP et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69 (4): 271–8.
13. Preston RA, Alonso A, Darlene P et al. Additive effect of Drospirenone/ 17b-Estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2005; 18: 797–804.
14. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011; 76 (7): 636–52.
15. Caprio M, Antelmi A, Chetrite G et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152 (1): 113–25.
16. Bachmann G, Korner P. Bleeding patterns associated with oral contraceptive use: a review of the literature. Contraception 2007; 76 (3): 182–9.
17. Endrikat JS, Milchev NP, Kapamadzija A et al. Bleeding pattern, tolerance and patient satisfaction with a drospirenonecontaining oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception 2009; 79 (6): 428–32.
18. Bruni Bresciani V. Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen. Minerva Ginecol 2010; 62 (3): 261–6.
19. Carranza-Lira S. Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausalvasomotor symptoms: a review. Clin Interv Aging 2009; 4: 59–62.
20. Chaiyasit N, Taneepanichskul S. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone – N24/4 regimen. J Med Assoc Thai 2010; 93 (5): 517–22.
21. Halpeich U, Backstrom T et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for research studies. Genecolodical Endocrinjlogy 2007; 23 (3): 123–30.
22. Gambacciani M, Rosano G, Cappagli B et al. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011; 14 (1): 18–24.
23. Ozdemir S, Görkemli H, Gezginç K et al. Clinical and metabolic effects of medroxyprogesterone acetate and ethinylestradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008; 103 (1): 44–9.
24. Chaikittisilpa S, Angsuwathana S, Chaovisitsaree S et al. Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women. J Med Assoc Thai 2011; 94 (9): 1019–25.
25. V. de Leo, Scolaro V, Musacchio MC et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 2011; 96 (4): 917–20.
26. Fruzzetti F, Perini D, Lazzarini V et al. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril 2010; 94 (5): 1793–8.
27. Anttila L, Bachmann G, Hernádi L et al. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 180–2.
28. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in postmenopausal women with hypertension. Hypertension 2006; 48: 1–8.
29. Ahmed AH, Gordon RD, Taylor PJ et al. Effect of contraceptives on aldosterone/renin ratio may vary according tothe components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 2011; 96 (6): 1797–804.
30. Dinger J, Minh TD, Buttmann N et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117 (1): 33–40.
31. Lima SM, Reis BF, Yamada SS et al. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium. Climacteric 2011; 14 (5): 551–7.
32. Kelly S, Davies E, Fearns S et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallelgroup, multicentre study. Clin Drug Investig 2010; 30 (5): 325–36.
33. Yildizhan R, Yildizhan B, Adali E et al. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet 2009; 280 (2): 255–61.
34. Lello S, Primavera G, Colonna L et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008; 24 (12): 718–23.
35. Gargano V, Massaro M, Morra I et al. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2008; 78 (1): 10–5.
36. Cibula D, Karck U, Weidenhammer HG et al. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20 mg and drospirenone 3 mg. Clin Drugs Investig 2006; 26 (3): 143–50.
37. Hernádi L, Marr J, Trummer D et al. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception 2009; 80 (1): 18–24.
38. Fan GS, Bian ML, Cheng LN et al. Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial. Zhonghua Fu Chan Ke Za Zhi 2009; 44 (1): 38–44.
39. Guang-Sheng F, Mei-Lu B, Li-Nan C et al. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin Drug Investig 2010; 30 (6): 387–96.
40. Huber J, Foidart JM, Wuttke W et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5 (1): 25–34.
41. Villaseca P, Hormaza P, Cardenas I et al. Eyhinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes. Eur J Contraception Reprod Health Care 2004; 9: 155–65.
42. Marr J, Heinemann K, Kunz M, Rapkin A. Ethinylestradiol 20 μg/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet 2011; 113 (2): 103–7.
43. Kiran H, Tok A, Yüksel M et al. Estradiol plus drospirenone therapy increases mammographic breast density in perimenopausal women. Eur J Obstet Gynecol Reprod Biol 2011; 159 (2): 384–7.
44. Foidart JM. Added benefits of drospirenone for compliance. Gynecol Endocrinol 2004; 18 (1): 33.
45. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004; 27 (13): 1001–18.
46. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71 (6): 409–16.
47. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005 (12): 716–27.
48. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 15 (2): CD006586.
49. Villa P, Suriano R, Ricciardi L et al. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemicmetabolism and other cardiovascular risk factors in healthy postmenopausal women. Fertil Steril 2011; 95 (1): 158–63.
50. Marr J, Gerlinger C, Kunz M. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen. Eur J Obstet Gynecol Reprod Biol 2012; 162 (1): 91–5.
51. Potter L, Oakley D, E. de Leon-Wong, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996 (28): 154–8.
52. Meier CR. Health risks of oral contraceptive. Ther Umsch 2011; 68 (6): 345–52.
53. Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med 2008; 53 (Suppl. 9): 721–8.
54. Oner G. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. Contraception 2011; 84 (5): 508–11.
55. Etminan M, Delaney JA, Bressler B et al. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011; 183 (8): 899–904.
56. Battaglia C, Mancini F, Fabbri R et al. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril 2010; 94 (4): 1417–25.
57. Marr J, Niknian M, Shulman LP, Lynen R. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen. Contraception 2011; 84 (1): 81–6.
58. Preston RA, Norris PM, Alonso AB et al. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007; 14 (3). Pt. 1: 408–14.
59. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl. 9): 729–41.
60. Rapkin AJ, Sorger SN, Winer SA. Drospirenone ethinylestradiol. Drugs Today (Barc) 2008; 44 (2): 133–45.
61. Rosenberg MJ. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30: 89–92, 104.
62. Rosendaal F. Female hormones and thrombosis. J Arterioscler Thromb Vascul Biol 2002; 22: 201–10.
63. Seeger H. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. Climacteric 2009; 12 (1): 80–7.
64. Sitruk-Ware R. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord 2011; 12 (2): 63–75.
65. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78 (1): 16–25.
66. Taneepanichskul S. Influence of a new oral contraceptive with drospirenone on lipid metabolism. Gynecol Endocrinol 2007; 23 (6): 347–50.
67. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 171–5.
68. Bitzer J, Frey B, M. von Schönau et al. Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: does it make a difference in the mind and the daily practise of gynaecologists and general practitioners? Eur J Contracept Reprod Health Care 2009; 14 (4): 258–67.
69. Joish VN, Boklage S, Lynen R et al. Use of drospirenone/ethinylestradiol (DRSP/EE) among women with acne reduces acne treatment-related resources. J Med Econ 2011; 14 (6): 681–9.
70. Verchaeghe J. Hormonal contraception in women with metabolic syndrome. Contraception Reprod Health Care 2010; 5 (5): 305–14.
________________________________________________
2. Кузнецова И.В., Побединский Н.М. Новый оральный контрацептив: один из многих или препарат с уникальными свойствами? Трудный пациент. 2004; 2: 11–4.
3. Подзолкова Н.М., Глазкова О.Л., Сумятина Л.В. Метаболические эффекты низкодозированных дроспиренонсодержащих гормональных контрацептивов. Рус. мед. журн. 2012; 17.
4. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата ЗГТ с дроспиреноном у пациенток с метаболическим синдромом в постменопаузе. Кардиоваскулярная терапия и профилактика. 2009; 8 (1): 75–80.
5. Lucky AW, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinylestradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82 (2): 143–50.
6. Meendering JR, Torgrimson BN, Miller NP et al. A combined oral contraceptive containing 30 mcg ethinylestradiol and 3.0 mg drospirenone does not impair endothelium-dependent vasodilation. Contraception 2010; 82 (4): 366–72.
7. Giribela CR, Melo NR, Silva RC et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 2012; 86 (1): 35–41.
8. Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5 (2): 124–34.
9. Gruber DM, Huber JC, Melis GB et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 m μg and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 m μg and desogestrel 150 m μg. Treat Endocrinol 2006; 5: 115–21.
10. Mabrouk M, Solfrini S, Frascà C et al. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg. Gynecol Endocrinol 2012; 28 (6): 451–4.
11. Maloney JM, Dietze P, Watson D et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009; 8 (9): 837–44.
12. Gaspard U, Endrikat L, Desager JP et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69 (4): 271–8.
13. Preston RA, Alonso A, Darlene P et al. Additive effect of Drospirenone/ 17b-Estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2005; 18: 797–804.
14. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011; 76 (7): 636–52.
15. Caprio M, Antelmi A, Chetrite G et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152 (1): 113–25.
16. Bachmann G, Korner P. Bleeding patterns associated with oral contraceptive use: a review of the literature. Contraception 2007; 76 (3): 182–9.
17. Endrikat JS, Milchev NP, Kapamadzija A et al. Bleeding pattern, tolerance and patient satisfaction with a drospirenonecontaining oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception 2009; 79 (6): 428–32.
18. Bruni Bresciani V. Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen. Minerva Ginecol 2010; 62 (3): 261–6.
19. Carranza-Lira S. Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausalvasomotor symptoms: a review. Clin Interv Aging 2009; 4: 59–62.
20. Chaiyasit N, Taneepanichskul S. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone – N24/4 regimen. J Med Assoc Thai 2010; 93 (5): 517–22.
21. Halpeich U, Backstrom T et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for research studies. Genecolodical Endocrinjlogy 2007; 23 (3): 123–30.
22. Gambacciani M, Rosano G, Cappagli B et al. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011; 14 (1): 18–24.
23. Ozdemir S, Görkemli H, Gezginç K et al. Clinical and metabolic effects of medroxyprogesterone acetate and ethinylestradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008; 103 (1): 44–9.
24. Chaikittisilpa S, Angsuwathana S, Chaovisitsaree S et al. Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women. J Med Assoc Thai 2011; 94 (9): 1019–25.
25. V. de Leo, Scolaro V, Musacchio MC et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 2011; 96 (4): 917–20.
26. Fruzzetti F, Perini D, Lazzarini V et al. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril 2010; 94 (5): 1793–8.
27. Anttila L, Bachmann G, Hernádi L et al. Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 μg/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 180–2.
28. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in postmenopausal women with hypertension. Hypertension 2006; 48: 1–8.
29. Ahmed AH, Gordon RD, Taylor PJ et al. Effect of contraceptives on aldosterone/renin ratio may vary according tothe components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 2011; 96 (6): 1797–804.
30. Dinger J, Minh TD, Buttmann N et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117 (1): 33–40.
31. Lima SM, Reis BF, Yamada SS et al. Effects of drospirenone/estradiol on steroid receptors and Bcl-2 in the postmenopausal endometrium. Climacteric 2011; 14 (5): 551–7.
32. Kelly S, Davies E, Fearns S et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallelgroup, multicentre study. Clin Drug Investig 2010; 30 (5): 325–36.
33. Yildizhan R, Yildizhan B, Adali E et al. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet 2009; 280 (2): 255–61.
34. Lello S, Primavera G, Colonna L et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008; 24 (12): 718–23.
35. Gargano V, Massaro M, Morra I et al. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2008; 78 (1): 10–5.
36. Cibula D, Karck U, Weidenhammer HG et al. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20 mg and drospirenone 3 mg. Clin Drugs Investig 2006; 26 (3): 143–50.
37. Hernádi L, Marr J, Trummer D et al. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception 2009; 80 (1): 18–24.
38. Fan GS, Bian ML, Cheng LN et al. Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial. Zhonghua Fu Chan Ke Za Zhi 2009; 44 (1): 38–44.
39. Guang-Sheng F, Mei-Lu B, Li-Nan C et al. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin Drug Investig 2010; 30 (6): 387–96.
40. Huber J, Foidart JM, Wuttke W et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5 (1): 25–34.
41. Villaseca P, Hormaza P, Cardenas I et al. Eyhinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes. Eur J Contraception Reprod Health Care 2004; 9: 155–65.
42. Marr J, Heinemann K, Kunz M, Rapkin A. Ethinylestradiol 20 μg/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet 2011; 113 (2): 103–7.
43. Kiran H, Tok A, Yüksel M et al. Estradiol plus drospirenone therapy increases mammographic breast density in perimenopausal women. Eur J Obstet Gynecol Reprod Biol 2011; 159 (2): 384–7.
44. Foidart JM. Added benefits of drospirenone for compliance. Gynecol Endocrinol 2004; 18 (1): 33.
45. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004; 27 (13): 1001–18.
46. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71 (6): 409–16.
47. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005 (12): 716–27.
48. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 15 (2): CD006586.
49. Villa P, Suriano R, Ricciardi L et al. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemicmetabolism and other cardiovascular risk factors in healthy postmenopausal women. Fertil Steril 2011; 95 (1): 158–63.
50. Marr J, Gerlinger C, Kunz M. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen. Eur J Obstet Gynecol Reprod Biol 2012; 162 (1): 91–5.
51. Potter L, Oakley D, E. de Leon-Wong, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996 (28): 154–8.
52. Meier CR. Health risks of oral contraceptive. Ther Umsch 2011; 68 (6): 345–52.
53. Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med 2008; 53 (Suppl. 9): 721–8.
54. Oner G. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. Contraception 2011; 84 (5): 508–11.
55. Etminan M, Delaney JA, Bressler B et al. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011; 183 (8): 899–904.
56. Battaglia C, Mancini F, Fabbri R et al. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril 2010; 94 (4): 1417–25.
57. Marr J, Niknian M, Shulman LP, Lynen R. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen. Contraception 2011; 84 (1): 81–6.
58. Preston RA, Norris PM, Alonso AB et al. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007; 14 (3). Pt. 1: 408–14.
59. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl. 9): 729–41.
60. Rapkin AJ, Sorger SN, Winer SA. Drospirenone ethinylestradiol. Drugs Today (Barc) 2008; 44 (2): 133–45.
61. Rosenberg MJ. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30: 89–92, 104.
62. Rosendaal F. Female hormones and thrombosis. J Arterioscler Thromb Vascul Biol 2002; 22: 201–10.
63. Seeger H. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. Climacteric 2009; 12 (1): 80–7.
64. Sitruk-Ware R. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord 2011; 12 (2): 63–75.
65. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78 (1): 16–25.
66. Taneepanichskul S. Influence of a new oral contraceptive with drospirenone on lipid metabolism. Gynecol Endocrinol 2007; 23 (6): 347–50.
67. Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155 (2): 171–5.
68. Bitzer J, Frey B, M. von Schönau et al. Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: does it make a difference in the mind and the daily practise of gynaecologists and general practitioners? Eur J Contracept Reprod Health Care 2009; 14 (4): 258–67.
69. Joish VN, Boklage S, Lynen R et al. Use of drospirenone/ethinylestradiol (DRSP/EE) among women with acne reduces acne treatment-related resources. J Med Econ 2011; 14 (6): 681–9.
70. Verchaeghe J. Hormonal contraception in women with metabolic syndrome. Contraception Reprod Health Care 2010; 5 (5): 305–14.
Авторы
А.Л.Унанян, Ю.М.Коссович
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.